Author name: Leonardo Arias

As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.

Los nanorrobots pueden parecer más ciencia-ficción que realidad, pero lo cierto es que la nanorrobótica se ha convertido en un campo de investigación que registra avances a buen ritmo. Usar nanorrobots se considera un enfoque prometedor para, por ejemplo, administrar sust …

Un cúmulo globular de la Vía Láctea es en realidad una estructura protogaláctica relativamente intacta que estuvo presente, aunque sin intervenir mucho, en la formación de nuestra galaxia y que constituye una reliquia de la infancia del universo.   As&iacute …

Se ha descubierto una nueva y sorprendente especie de araña en la selva del norte de Queensland, en Australia, que teje una ingeniosa y robusta trampa accionada por resorte para atrapar, de una en una, hormigas de una misma especie. La pericia en confeccionar la trampa, así como el gra …

With drug pricing now embedded in U.S. policy, business development teams in biotech and pharma are changing the way they strike deals, including acknowledging policy uncertainties with renegotiation clauses.

Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.

While existing antibody-drug conjugates have been incredible advancements in cancer care, patients are ready for a better experience. At the BIO International Convention in San Diego on Thursday, BioSpace will lead a discussion on the next generation of ADCs.

Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—will account for nearly half of the total sales of the top 10 drugs in 2032.

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Having stuck with local production in the years when offshoring to lower-cost locations was in fashion, Aquestive’s CEO is well placed to explain what the recent reshoring drive means for manufacturers.